ymptoms. Thus, the present analyses were based on the remaining 1975 participants. Measurement of the urinary excretion of 8-iso-PGF2a has been demonstrated to be a reliable marker of lipid peroxidation in vivo. Morning spot urine samples were collected from participants at their second annual clinical visit and stored at 270uC for subsequent analyses. Urinary concentrations of 8-iso-PGF2a were measured by order 1235481-90-9 previously validated radioimmunoassay methods at the Laboratory of Clinical Pharmacology of Eicosanoids and Pharmacodynamic located in the Center of Excellence on Aging at the “Gabriele D’Annnunzio”University Foundation. Measurements of urinary eicosanoid metabolites by RIA methods have been validated with different antisera and by comparison with gas chromatography-mass spectrometry. The intra-assay and inter-assay coefficients of variation for the 8-iso-PGF2a were 2.0% 16824511 and 2.9% at the lowest level of standard, and 3.7% and 10.8% at the highest level of standard, respectively. Urinary levels of 8-isoPGF2a were adjusted for urinary creatinine to account for differences in renal excretory function. In the present analyses, concentration of 8-isoPGF2a was considered as a continuous measure as well as a dichotomous categorical variable. Covariates Covariates were a priori selected on the basis of previously reported associations with depression and oxidative stress. Sociodemographic variables included age, sex, race, educational attainment. Because a difference in median 8-iso-PGF2a across study sites was found, this covariate was retained in multivariate analyses. Alcohol consumption was assessed using a standardized questionnaire and categorized as never,,1 drink/week, 17 drinks/week and.7 drinks/week. Body mass index was calculated as kg/m2 and categorized as normal, overweight and obese. Presence of cardiovascular diseases, cerebrovascular diseases and diabetes were specifically 
ascertained using standardized algorithms, considering various Oxidative Damage and Depression in the Elderly information including self-report, medications, clinical findings, and medical claims data from the former Health Care Financing Administration. Each disease variable was then updated taking into account the new diagnoses and events reported by participants or determined by review of clinical documentation in the year prior to the second visit. Since smoking status, comprehensive physical activity participation and cognitive function were not assessed at the second visit, these variables derive from data collected at the first Health ABC study visit. These dimensions are less likely to change during a 1-year period in this sample of well-functioning older persons. Smoking status was coded as non-smoker/former/current smoker. Physical activity was estimated through a specific questionnaire on the basis of to time/intensity spent on physical activities. Cognitive status was evaluated with the Modified Mini Mental State Examination . Statistical Analyses Variables are presented as percentages, means or median. Univariate differences in sample characteristics were tested using chi-square or Kruskal-Wallis ANOVA, as appropriate. Differences in adjusted means of 8-iso-PGF2a across depression status were examined using analyses of co-variance. For significant differences 18004284 Cohen’s d was calculated as a measure of effect size. In these analyses, concentrations of 8-iso-PGF2a were log-transformed due to skewed distribution and mean values were presented backtran
bet-bromodomain.com
BET Bromodomain Inhibitor
